Paracetamol 10 mg/ml solution for infusion clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).
This study is testing a new cell therapy called ALLO-501A, along with another drug called ALLO-647, for adults with a type of blood cancer called Large B-Cell Lymphoma, where previous treatments haven't worked. It aims to see how safe and effective these new treatments are.
For: Large B-Cell Lymphoma (LBCL)Italy · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy
This study is testing a new way to prepare people with a type of lymphoma (LBCL) for a special cell therapy called ALLO-501A. It compares two methods of preparing the body to see which works best and is safest.
For: Large B-Cell Lymphoma (LBCL)Belgium · Germany · Austria - AuthorisedTherapeutic confirmatory (Phase III)
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma
This study is testing new treatments for a type of blood cancer called multiple myeloma that has come back or isn't responding to previous treatments. It compares new drugs, Linvoseltamab alone or with Carfilzomib, against standard treatments to see how well they work and if they are safe.
For: Relapsed Refractory Multiple MyelomaGreece · Spain · Poland